GIP/GLP-1RA as adjunctive to automated insulin delivery in adults with Type 1 diabetes (the AID-JUNCT trial): Study protocol for a prospective, randomized, clinical trial

What Was Tested

Researchers studied GIP (Gastric Inhibitory Polypeptide) in this clinical study publication.

However, randomized controlled trials (RCT) are still insufficient.

Who Took Part

The abstract describes 42 participants taking part.

The age groups tagged for this paper are teenagers, young adults, adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, open-label and parallel-group study.

Because people in this GIP (Gastric Inhibitory Polypeptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Nothing was hidden in this open-label GIP (Gastric Inhibitory Polypeptide) study: the participants and staff both knew the treatment.

Groups ran in parallel: each of the participants stayed in one arm throughout.

The exploratory endpoints include: the change in body mass index (BMI), liver steatosis (MASLD), and body composition.

Safety outcomes include severe hypoglycemia, diabetic ketoacidosis (DKA), and refractory gastrointestinal side effects.

What Was Measured

PubMed files the paper under topics including Diabetes Mellitus, Type 1, Insulin, Gastric Inhibitory Polypeptide, Hypoglycemic Agents, Blood Glucose, Randomized Controlled Trials as Topic and Equivalence Trials as Topic.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of GIP (Gastric Inhibitory Polypeptide) in 42 participants.

The abstract goes on to report its results in about 2 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (PloS one), a journal based in United States.

More context: the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.